SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a significant surge in investor interest and bullish momentum following optimistic commentary from the CEO regarding survival data from its ongoing REGAL Phase 3 clinical trial. The community is actively discussing the potential for a short squeeze as institutional accumulation increases ahead of the anticipated 80th trial event, with many retail investors viewing the company's immunotherapy platform as a major, de-risked candidate for future valuation growth.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is the central focus of market attention as investors eagerly await earnings results, with the community sharply divided between those betting on a massive breakout driven by relentless AI infrastructure demand and those fearing a potential "sell-the-news" correction. Traders are closely analyzing options volatility and historical post-earnings patterns to navigate the uncertainty, as the stock's performance is widely expected to set the tone for the broader tech sector and the overall market direction.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the FDA's acceptance of the supplemental BLA for ANKTIVA in papillary-only bladder cancer with a PDUFA date of January 6, 2027. The community is actively discussing the stock's potential for label expansion and market dominance, while retail investors continue to debate the impact of short selling activity and the broader implications of NCCN guideline support on patient access.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar Automotive Holding UK PLC

Polestar is currently drawing significant community attention as investors weigh a recent financing boost against persistent concerns regarding cash burn, negative margins, and ongoing tariff challenges. While the community remains divided over the company's long-term survival, discussions are heavily focused on the brand's upcoming model pipeline and its ability to scale production across global markets.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates its price action and long-term viability ahead of the upcoming Q1 earnings report, with bulls focusing on improved vehicle margins and new product launches like the Onvo L80, while bears highlight persistent dilution concerns and ongoing volatility. Despite strong delivery growth and institutional buying activity, sentiment remains divided, fueled by intense discussions regarding market manipulation and the broader challenges facing Chinese EV stocks listed on U.S. exchanges.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is currently generating significant community buzz as investors weigh its potential pivot into AI infrastructure against skepticism regarding the timing of promised hyperscaler deals. While bullish traders are looking for a short squeeze fueled by high short interest and anticipation of contract announcements, others remain cautious due to ongoing losses and the execution risks associated with its massive power pipeline.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is currently trending as investors debate whether the recent pullback signals an exhaustion of the small-cap rally or a healthy consolidation amid persistent inflation concerns and rising Treasury yields. Community sentiment is deeply divided, with many traders closely monitoring IWM's relationship to key gamma flip points and broader market breadth, while others interpret the index's relative weakness as a potential precursor to a broader market rotation.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently under heavy selling pressure as rising global yields and intensifying inflation concerns, fueled by geopolitical conflicts and supply shocks, have investors questioning the sustainability of current bond valuations. The community is actively debating whether the current selloff represents a structural breakdown driven by U.S. debt and deficit concerns, or a tactical opportunity ahead of potential central bank interventions and Fed policy shifts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently at the center of intense debate following positive Phase 3 trial results for its HAE gene-editing therapy, with investors weighing the breakthrough clinical success against concerns regarding a recent share offering and heavy short interest. While the community is split between bullish sentiment over long-term commercial potential and frustration over short-term price manipulation and volatility, active discussions are focused on whether current institutional accumulation will trigger a squeeze or if the dilution will continue to weigh on shares.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing significant attention as institutional ownership climbs, with investors optimistic about the clinical data for NXC-201 in treating relapsed/refractory AL amyloidosis. The community is focused on the path toward a BLA submission and the potential for a strategic partnership or acquisition, viewing the company's strong cash position and regulatory progress as key drivers for long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Rongho99xncom

Rongho99